Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2021-06-03
2021-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers
NCT04424017
Assessment of Sexual Dysfunction Among COVID-19 Recovered Patients
NCT05148819
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak
NCT04426292
Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs
NCT04563247
Serological Surveillance for COVID-19 in Central North Carolina
NCT04490174
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A cross-sectional study to detect the seroprevalence to COVID 19 in chronic hemodialysis patients and compare it with the COVID 19 seroprevalence in healthy control in Sohag governorate Egypt
Methods:
After taken informed consent according to Sohag University Ethical Committee A questionnaire on coronavirus symptoms will be asked including epidemiological characters and history of previous COVID 19 infection and infection control measures to prevent it
5 ml of the blood sample will be taken for IgG antibodies testing with a chemiluminescent microparticle immunoassay.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1 chronic haemodialysis patients
seroprevalnce of COVID 19
laboratory test
seroprevalnce
healthy control
seroprevalnce of COVID 19
laboratory test
seroprevalnce
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
laboratory test
seroprevalnce
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Noha Saber Shafik
lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
N S shafik, lecturer
Role: PRINCIPAL_INVESTIGATOR
Sohag University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-21-04-33
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.